UNSPSC 51386007: Duometacin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H19NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L5WVJ201KN, chemically known as 1h-indole-1-acetic acid, 6-methoxy-3-(4-methoxybenzoyl)-2-methyl- but generally known as duometacin, which bears US NIH Compound Identifier 71912. European Medicines Agency schedules Duometacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06427MIG.

UNSPSC 51386007 Duometacin, a Commodity code, does not align with the state and local procurement activity recently tagged under it. The code nominally describes a specific pharmaceutical compound, yet the recent opportunities posted under this code solicit naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals through cooperative purchasing — none of which involve duometacin. The mismatch between the code's narrow pharmaceutical-substance focus and the broader pharmacy procurement and harm-reduction supply activity appearing in the tagged opportunities suggests either systematic miscoding or that this code receives minimal relevant activity in state and local procurement channels. State and local issuing bodies posting under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances; the issuing bodies are geographically dispersed across Florida, Texas, and Minnesota, each pursuing distinct pharmacy-related products and programs rather than duometacin specifically.

Representative recent opportunities illustrate the scope mismatch. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through electronic bidding with a due date of July 26, 2023 (a retroactive date suggesting data anomalies). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 establishing multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals due March 26, 2026. None of these solicitations involve duometacin or a single-substance pharmaceutical procurement. Absent clear recent activity specifically targeting duometacin, this code shows little actionable signal for vendors pursuing genuine pharmaceutical-compound opportunities in the state and local market.